Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme

Bulletin Express05-20 19:22

Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has authorised the trustee of its H Share Award Scheme to buy additional H shares on the open market for an aggregate consideration of up to US$50.00 million. Purchases will be executed at prevailing market prices and will be financed entirely from the company’s internal resources.

The acquired stock will form a reserve of “Target Shares” to satisfy future share awards for eligible employees, contingent on meeting the scheme’s vesting conditions. The trustee, which had already bought H shares in 2025 under earlier instructions, will hold the new shares without exercising voting rights.

Management stated that building a competitively priced share reserve will enhance flexibility in structuring remuneration, bolstering talent attraction and retention. The board emphasised that the planned acquisitions will not affect day-to-day operations and that the group retains a solid financial position.

Execution of the share purchases remains subject to market conditions; the board retains full discretion over timing, quantity and pricing, and may ultimately decide not to proceed with any purchases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158348933?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158348933","market":"hk","top_or_hot":-1,"title":"Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme","media":"Bulletin Express","content":"<p>Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has authorised the trustee of its H Share Award Scheme to buy additional H shares on the open market for an aggregate consideration of up to US$50.00 million. Purchases will be executed at prevailing market prices and will be financed entirely from the company’s internal resources.</p>\n<p>The acquired stock will form a reserve of “Target Shares” to satisfy future share awards for eligible employees, contingent on meeting the scheme’s vesting conditions. The trustee, which had already bought H shares in 2025 under earlier instructions, will hold the new shares without exercising voting rights.</p>\n<p>Management stated that building a competitively priced share reserve will enhance flexibility in structuring remuneration, bolstering talent attraction and retention. The board emphasised that the planned acquisitions will not affect day-to-day operations and that the group retains a solid financial position.</p>\n<p>Execution of the share purchases remains subject to market conditions; the board retains full discretion over timing, quantity and pricing, and may ultimately decide not to proceed with any purchases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-20 19:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has authorised the trustee of its H Share Award Scheme to buy additional H shares on the open market for an aggregate consideration of up to US$50.00 million. Purchases will be executed at prevailing market prices and will be financed entirely from the company’s internal resources.</p>\n<p>The acquired stock will form a reserve of “Target Shares” to satisfy future share awards for eligible employees, contingent on meeting the scheme’s vesting conditions. The trustee, which had already bought H shares in 2025 under earlier instructions, will hold the new shares without exercising voting rights.</p>\n<p>Management stated that building a competitively priced share reserve will enhance flexibility in structuring remuneration, bolstering talent attraction and retention. The board emphasised that the planned acquisitions will not affect day-to-day operations and that the group retains a solid financial position.</p>\n<p>Execution of the share purchases remains subject to market conditions; the board retains full discretion over timing, quantity and pricing, and may ultimately decide not to proceed with any purchases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1158348933","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158348933","pubTimestamp":1779276169,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has authorised the trustee of its H Share Award Scheme to buy additional H shares on the open market for an aggregate consideration of up to US$50.00...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"领投Biolabs斥资高达5,000万美元由受托人主导购买H股，用于员工奖励计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has authorised the trustee of its H Share Award Scheme to buy additional H shares on the open market for an aggregate consideration of up to US$50.00 million. Purchases will be executed at prevailing market prices and will be financed entirely from the company’s internal resources.\nThe acquired stock will form a reserve of “Target Shares” to satisfy future share awards for eligible employees, contingent on meeting the scheme’s vesting conditions. The trustee, which had already bought H shares in 2025 under earlier instructions, will hold the new shares without exercising voting rights.\nManagement stated that building a competitively priced share reserve will enhance flexibility in structuring remuneration, bolstering talent attraction and retention. The board emphasised that the planned acquisitions will not affect day-to-day operations and that the group retains a solid financial position.\nExecution of the share purchases remains subject to market conditions; the board retains full discretion over timing, quantity and pricing, and may ultimately decide not to proceed with any purchases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158348933","isCrawlerRequest":true}